Meta-analysis finds BCI_net prognostic for overall survival in oral squamous cell carcinoma
A new cancer test reads tumor cell chats to predict survival
This meta-analysis of 2 cohorts (TCGA-HNSC n=519, GSE65858 n=270) found that the BCI_net directional composite was independently associated …
Your cancer cells may be chatting with each other, and a new test that listens to those conversations could predict how aggressive the disea…
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
A New Drug Sequence Shrank Lung Tumors When Others Failed
This is a case report with literature review of a 79-year-old male with MET exon 14 skipping non-small cell lung cancer and high PD-L1 expre…
A 79-year-old man's lung tumors shrank when doctors switched his drug sequence, offering a clue for others with hard-to-treat cancer.
Narrative review on therapeutic cancer vaccines for head and neck squamous cell carcinoma
Review discusses cancer vaccines for head and neck cancer
This narrative review synthesizes evidence on therapeutic cancer vaccines, including personalized vaccines, for head and neck squamous cell …
This review looks at how cancer vaccines might work alongside other treatments for head and neck squamous cell carcinoma.
Meta-analysis of molecular testing for indeterminate thyroid nodules finds lower surgical rates
New Test Cuts Unnecessary Thyroid Surgeries by Half for Many Patients
This meta-analysis of molecular testing for thyroid nodules with indeterminate cytology found that conventional management led to significan…
• Molecular testing slashes surgery rates for unclear thyroid biopsies • Helps 30 million people yearly avoid risky operations • Second gene…
Meta-analysis compares endoscopic transorbital and transcranial approaches for spheno-orbital meningioma
Surgeons Fix Bulging Eyes Without Traditional Brain Surgery Scars
This meta-analysis of 2016 patients compared endoscopic transorbital (ETOA) versus transcranial approaches for spheno-orbital meningioma. ET…
• New eye socket surgery fixes bulging eyes better than old methods • Helps patients wanting less scarring and faster recovery • Tumor remov…
Meta-analysis finds no overall link between chronic pain and cancer mortality but notes potential site-specific risks
Chronic pain does not raise overall cancer risk in this new review
This systematic review and meta-analysis evaluated 23 studies involving patients with chronic pain featuring minimal or non-inflammatory fea…
New research shows chronic pain does not increase overall cancer risk, offering relief to millions worried about their health.
FDA Approves Vabrinty (leuprolide acetate) for Advanced Prostate Cancer
FDA approves new drug Vabrinty for advanced prostate cancer.
The FDA approved Vabrinty (leuprolide acetate) for the treatment of advanced prostate cancer. It is a GnRH agonist administered subcutaneous…
The FDA approved Vabrinty (leuprolide acetate) to treat advanced prostate cancer. It is a hormone therapy that lowers testosterone levels. T…
FDA Approves Talvey (talquetamab) for Relapsed/Refractory Multiple Myeloma
FDA approves new multiple myeloma drug Talvey for certain patients.
The FDA has approved Talvey (talquetamab) for adult patients with relapsed or refractory multiple myeloma who have received at least four pr…
The FDA approved Talvey (talquetamab) for adults with multiple myeloma who have tried at least four other treatments. It is for patients who…
FDA Approves Tecvayli (teclistamab) for Relapsed or Refractory Multiple Myeloma
FDA approves new drug Tecvayli for advanced multiple myeloma.
The FDA approved Tecvayli (teclistamab) for relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj a…
The FDA approved Tecvayli (teclistamab) for adults with multiple myeloma that has come back or not responded to treatment. It is used alone …
FDA Approves Zoladex (goserelin) for Multiple Indications Including Prostate Cancer and Endometriosis
FDA approves Zoladex for prostate cancer, endometriosis, and breast cancer.
The FDA approved Zoladex (goserelin) for use in combination with flutamide for locally confined prostate cancer, palliative treatment of adv…
The FDA has approved Zoladex (goserelin) to treat prostate cancer, endometriosis, and advanced breast cancer. It is given as a shot every 28…
FDA Approves VABRINTY (leuprolide acetate) for Advanced Prostate Cancer
FDA approves Vabrinty for advanced prostate cancer with flexible dosing.
The FDA approved VABRINTY (leuprolide acetate) for the treatment of advanced prostate cancer. It is a GnRH agonist administered subcutaneous…
The FDA approved Vabrinty (leuprolide acetate) for advanced prostate cancer. It is a hormone therapy given as a shot every 1 to 6 months. Th…
FDA Approves Zoladex (goserelin) for Locally Confined and Advanced Prostate Cancer
FDA approves Zoladex for prostate cancer treatment.
FDA approved Zoladex (goserelin) for use in combination with flutamide for locally confined stage T2b-T4 prostate cancer and as palliative t…
The FDA approved Zoladex (goserelin) for two uses in prostate cancer: with radiation for early stage cancer and as palliative care for advan…